Coversyl Plus Adverse Reactions

Summary of safety profile: The administration of perindopril inhibits the renin-angiotensin-aldosterone axis and tends to reduce the potassium loss caused by indapamide.
Four percent of the patients on treatment with Coversyl Plus 5mg/1.25mg experience hypokalaemia(potassium level < 3.4 mmol/l).
Six percent of the patients on treatment with Coversyl Plus 10mg/2.5mg experience hypokalaemia (potassium level < 3.4 mmol/l).
The most commonly reported adverse reactions observed are: with perindopril: dizziness, headache, paraesthesia, dysgeusia, visual impairment, vertigo, tinnitus, hypotension, cough, dyspnoea, abdominal pain, constipation, dyspepsia, diarrhoea, nausea, vomiting, pruritus, rash, muscle cramps and asthenia; with indapamide: hypersensitivity reactions, mainly dermatological, in subjects with a predisposition to allergic and asthmatic reactions and maculopapular rashes.
Tabulated list of adverse reactions: The following undesirable effects have been observed during clinical trials and/or post-marketing use and ranked under the following frequency: Very common (≥1/10); common (≥1/100, <1/10); uncommon (≥1/1000, <1/100); rare (≥1/10000,<1/1000), very rare (<1/10000), not known (cannot be estimated from the available data). (See Tables A and B.)

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image

Cases of SIADH have been reported with other ACE inhibitors. SIADH can be considered as a very rare but possible complication associated with ACE inhibitor therapy including perindopril.
Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.